| 51 |
25458015 | Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment. | 2015 Feb |
4 |
| 52 |
25639617 | Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib. | 2015 Mar-Apr |
1 |
| 53 |
25907705 | Axitinib in metastatic renal cell carcinoma. | 2015 May |
1 |
| 54 |
26042424 | The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. | 2015 |
2 |
| 55 |
26067856 | Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of Granulosa Cell Tumors of the Ovary. | 2015 Sep |
1 |
| 56 |
26380584 | Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells. | 2015 |
1 |
| 57 |
26408725 | Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma. | 2015 Oct |
1 |
| 58 |
26484875 | Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors. | 2015 Dec 15 |
2 |
| 59 |
24127298 | Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. | 2014 Aug 15 |
2 |
| 60 |
24185817 | Sunitinib--CLIO conjugate: a VEGFR/PDGFR-targeting active MR probe. | 2014 Jun |
4 |
| 61 |
24704536 | The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. | 2014 Apr |
1 |
| 62 |
24723451 | Culture dimensionality influences the resistance of glioblastoma stem-like cells to multikinase inhibitors. | 2014 Jun |
1 |
| 63 |
24743196 | [Renal cell carcinoma]. | 2014 Feb |
1 |
| 64 |
24756791 | Sunitinib in the treatment of advanced solid tumors. | 2014 |
2 |
| 65 |
24783183 | Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor. | 2014 Apr |
2 |
| 66 |
24786599 | Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. | 2014 May 27 |
1 |
| 67 |
24842548 | Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. | 2014 Aug |
2 |
| 68 |
24927771 | Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. | 2014 Sep |
1 |
| 69 |
25058995 | Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. | 2014 Jun |
1 |
| 70 |
25076341 | Targeted agents in treatment of neuroendocrine tumors of pancreas. | 2014 Jul 28 |
2 |
| 71 |
25085632 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. | 2014 Aug 1 |
6 |
| 72 |
25151214 | Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. | 2014 Dec |
2 |
| 73 |
25228815 | Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells. | 2014 |
3 |
| 74 |
25299731 | Unbinding pathways of VEGFR2 inhibitors revealed by steered molecular dynamics. | 2014 Nov 24 |
1 |
| 75 |
25336977 | Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. | 2014 |
1 |
| 76 |
25353068 | VEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. | 2014 Dec 10 |
1 |
| 77 |
21478036 | Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. | 2013 May |
3 |
| 78 |
23322198 | Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. | 2013 Feb 5 |
2 |
| 79 |
23336010 | Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. | 2013 |
1 |
| 80 |
23398161 | Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. | 2013 Feb |
2 |
| 81 |
23399884 | Synthesis of 5-(ethylsulfonyl)-2-methoxyaniline: An important pharmacological fragment of VEGFR2 and other inhibitors. | 2013 |
1 |
| 82 |
23475388 | Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. | 2013 Sep |
1 |
| 83 |
23492365 | Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor-associated macrophages. | 2013 May 15 |
2 |
| 84 |
23507600 | [A case of male breast cancer for which mTOR inhibitor was effective with advanced renal cancer]. | 2013 Mar |
1 |
| 85 |
23511629 | VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. | 2013 Mar 19 |
1 |
| 86 |
23601669 | The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come? | 2013 Jul |
2 |
| 87 |
23626551 | Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports. | 2013 Jan |
1 |
| 88 |
23969186 | Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. | 2013 Sep |
1 |
| 89 |
24061866 | Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis. | 2013 Dec |
1 |
| 90 |
24123039 | Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib. | 2013 Oct |
2 |
| 91 |
24640739 | [VEGFRs in neoplastic angiogenesis and prospects for therapy of brain tumors]. | 2013 |
1 |
| 92 |
21445974 | Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. | 2012 Feb 15 |
1 |
| 93 |
21699503 | Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells. | 2012 Jan |
2 |
| 94 |
21953673 | Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. | 2012 Aug 15 |
1 |
| 95 |
22015552 | Gastrointestinal stromal tumors. | 2012 |
4 |
| 96 |
22207048 | VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. | 2012 Aug |
3 |
| 97 |
22237457 | Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. | 2012 Apr |
1 |
| 98 |
22289686 | Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. | 2012 Dec |
1 |
| 99 |
22317769 | A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. | 2012 Sep |
2 |
| 100 |
22395469 | Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. | 2012 Feb |
1 |